Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback